TCTR20210125002已完成3 期
Efficacy of povidone iodine spray for SARS-CoV-2 eradication in upper respiratory tract of patients with COVID-19: A pilot study
Health System Research Institute (HSRI)0 个研究点目标入组 14 人开始时间: 2021年1月25日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
0.4% PVP-I nasal spray demonstrated minimal virucidal efficacy at 3 minutes post-exposure. At 4 hours post-exposure, the viral titer was unchanged from baseline. The poor virucidal activity of 0.4% PVP-I nasal spray is unlikely to reduce transmission of SARS-CoV-2. The 0.4% PVP-I nasal spray was well-tolerated.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •1. Age 18-60 years,
- •2. Asymptomatic or mild symptom of COVID-19 by RT-PCR,
- •3. Willing to participate in the present study,
- •4. Cycle threshold of RT-PCR for SARS-CoV-2 less than 25 (within 3 days before enrollment)
排除标准
- •1. Severe allergy to seafood or iodine,
- •2. Pregnancy or lactation,
- •3. Thyroid gland enlargement or thyrotoxicosis,
- •4. Receiving favipiravir or remdesivir treatment before enrollment
研究者
相似试验
Unknown
4 期
Halodine Nasal Antiseptic in Patients With COVID-19SARS-CoV-2 InfectionNCT04517188Halodine LLC40
Unknown
1 期
Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy SubjectsCovid19Povidone Iodine Adverse ReactionNCT04510402Brigham and Women's Hospital50
已完成
1 期
Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.COVID-19 PositiveInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12621000034831Firebrick Pharma Limited23
进行中（未招募）
不适用
A pilot study of the ability of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash to kill the SARS-CoV-2 virus in people with COVID-19ISRCTN13447477Royal Surrey County Hospital NHS Foundation Trust22
终止
1 期
A phase I/II study of povidone-iodine nasal spray (Nasodine”) to investigate safety and tolerability in healthy volunteers (Stage 1), and to investigate safety and efficacy in patients with the common cold (Stage 2).Common ColdInfection - Other infectious diseasesACTRN12618001244291Firebrick Pharma Pty Ltd49